HomeCompareHBMHF vs PLD

HBMHF vs PLD: Dividend Comparison 2026

HBMHF yields 128.21% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HBMHF wins by $5.69M in total portfolio value
10 years
HBMHF
HBMHF
● Live price
128.21%
Share price
$1.56
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11.60M
Annual income
$4,575,129.27
Full HBMHF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — HBMHF vs PLD

📍 HBMHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHBMHFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HBMHF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HBMHF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBMHF
Annual income on $10K today (after 15% tax)
$10,897.44/yr
After 10yr DRIP, annual income (after tax)
$3,888,859.88/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $149,256.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBMHF + PLD for your $10,000?

HBMHF: 50%PLD: 50%
100% PLD50/50100% HBMHF
Portfolio after 10yr
$8.75M
Annual income
$4,662,927.22/yr
Blended yield
53.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

HBMHF
No analyst data
Altman Z
8.0
Piotroski
7/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBMHF buys
0
PLD buys
0
No recent congressional trades found for HBMHF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHBMHFPLD
Forward yield128.21%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$11.60M$5.91M
Annual income after 10y$4,575,129.27$4,750,725.19
Total dividends collected$10.60M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: HBMHF vs PLD ($10,000, DRIP)

YearHBMHF PortfolioHBMHF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$23,521$12,820.51$11,241$540.96+$12.3KHBMHF
2$53,349$28,181.78$13,019$991.13+$40.3KHBMHF
3$116,823$59,739.54$15,801$1,870.97+$101.0KHBMHF
4$247,259$122,259.11$20,609$3,701.21+$226.7KHBMHF
5$506,405$241,837.18$29,919$7,867.97+$476.5KHBMHF
6$1,004,750$462,896.88$50,631$18,617.74+$954.1KHBMHF
7$1,933,425$858,342.70$105,528$51,352.20+$1.83MHBMHF
8$3,612,406$1,543,641.03$287,364$174,449.42+$3.33MHBMHF
9$6,560,727$2,695,452.74$1,081,760$774,280.77+$5.48MHBMHF
10$11,595,107$4,575,129.27$5,908,209$4,750,725.19+$5.69MHBMHF

HBMHF vs PLD: Complete Analysis 2026

HBMHFStock

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

Full HBMHF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this HBMHF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBMHF vs SCHDHBMHF vs JEPIHBMHF vs OHBMHF vs KOHBMHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.